Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd., engages in the development of new drugs with non-new ingredients in Taiwan. It develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic. The company was founded in 2011 an… Read more
Original BioMedicals Co., Ltd. (6483) - Total Liabilities
Latest total liabilities as of June 2025: NT$23.19 Million TWD
Based on the latest financial reports, Original BioMedicals Co., Ltd. (6483) has total liabilities worth NT$23.19 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Original BioMedicals Co., Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Original BioMedicals Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Original BioMedicals Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Original BioMedicals Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grand Baoxin Auto Group Limited
PINK:GBXXY
|
USA | $13.46 Billion |
|
Quonia SOCIMI SA
MC:YQUO
|
Spain | €12.15 Million |
|
J8D0
F:J8D0
|
Germany | €258.64 Million |
|
TMT Steel Public Company Limited
BK:TMT
|
Thailand | ฿5.54 Billion |
|
MCH Group AG
SW:MCHN
|
Switzerland | CHF269.06 Million |
|
Q linea AB
ST:QLINEA
|
Sweden | Skr31.66 Million |
|
Perfect Medical Industry Co., Ltd.
TWO:6543
|
Taiwan | NT$469.95 Million |
|
Rumble Resources Ltd
AU:RTR
|
Australia | AU$1.52 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Original BioMedicals Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Original BioMedicals Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Original BioMedicals Co., Ltd. (2019–2024)
The table below shows the annual total liabilities of Original BioMedicals Co., Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$24.12 Million | -42.67% |
| 2023-12-31 | NT$42.07 Million | +45.74% |
| 2022-12-31 | NT$28.86 Million | +2.13% |
| 2021-12-31 | NT$28.26 Million | -3.99% |
| 2020-12-31 | NT$29.44 Million | -11.78% |
| 2019-12-31 | NT$33.37 Million | -- |